Found: 8
Select item for more details and to access through your institution.
B‐cell frequencies and immunoregulatory phenotypes in myeloproliferative neoplasms: Influence of ruxolitinib, interferon‐α2, or combination treatment.
- Published in:
- European Journal of Haematology, 2019, v. 103, n. 4, p. 351, doi. 10.1111/ejh.13292
- By:
- Publication type:
- Article
The impact of ruxolitinib treatment on inflammation-mediated comorbidities in myelofibrosis and related neoplasms.
- Published in:
- Clinical Case Reports, 2015, v. 3, n. 6, p. 499, doi. 10.1002/ccr3.281
- By:
- Publication type:
- Article
Safety and efficacy of combination therapy of interferon‐α2 and ruxolitinib in polycythemia vera and myelofibrosis.
- Published in:
- Cancer Medicine, 2018, v. 7, n. 8, p. 3571, doi. 10.1002/cam4.1619
- By:
- Publication type:
- Article
Severity and 90-day survival of SARS-CoV-2 infection among patients with haematological disorders.
- Published in:
- Acta Oncologica, 2022, v. 61, n. 4, p. 500, doi. 10.1080/0284186X.2022.2026464
- By:
- Publication type:
- Article
Circulating YKL-40 in myelofibrosis a potential novel biomarker of disease activity and the inflammatory state.
- Published in:
- European Journal of Haematology, 2014, v. 93, n. 3, p. 224, doi. 10.1111/ejh.12332
- By:
- Publication type:
- Article
Reduced glutathione as a physiological co-activator in the activation of peptidylarginine deiminase.
- Published in:
- Arthritis Research & Therapy, 2016, v. 18, p. 1, doi. 10.1186/s13075-016-1000-7
- By:
- Publication type:
- Article
MPNs as Inflammatory Diseases: The Evidence, Consequences, and Perspectives.
- Published in:
- Mediators of Inflammation, 2015, v. 2015, p. 1, doi. 10.1155/2015/102476
- By:
- Publication type:
- Article
The Role of Reactive Oxygen Species in Myelofibrosis and Related Neoplasms.
- Published in:
- Mediators of Inflammation, 2015, v. 2015, p. 1, doi. 10.1155/2015/648090
- By:
- Publication type:
- Article